Scarring Alopecia: Why Prompt Treatment Matters and What to Expect

What makes scarring alopecia different from other hair loss?

Most forms of hair loss spare the follicle itself. In pattern hair loss, telogen effluvium, and alopecia areata, the follicle remains present but dormant or miniaturized — with effective treatment, hair can regrow. Scarring alopecia is fundamentally different: the inflammation targets and permanently destroys the follicle, replacing it with scar tissue 1Ref 1Harries M, Tosti A, Messenger A (updated by NCBI Bookshelf contributors) (2023).Central Centrifugal Cicatricial Alopecia — StatPearls.Classification of primary scarring alopecias into lymphocytic, neutrophilic, and mixed types; mechanism of permanent follicle destruction by inflammation and replacement with scar tissue. Once a follicle is scarred, hair cannot grow from that location again.

This distinction drives everything about management. The urgency of treatment is not about recovering lost hair — it is about preserving follicles you still have. The window for intervention closes permanently as each follicle is destroyed.

The term "scarring alopecia" covers a spectrum of distinct diseases that happen to share this common mechanism. They are classified by the type of inflammation involved: lymphocytic (the most common group, including lichen planopilaris and frontal fibrosing alopecia), neutrophilic, and mixed 1Ref 1Harries M, Tosti A, Messenger A (updated by NCBI Bookshelf contributors) (2023).Central Centrifugal Cicatricial Alopecia — StatPearls.Classification of primary scarring alopecias into lymphocytic, neutrophilic, and mixed types; mechanism of permanent follicle destruction by inflammation and replacement with scar tissue.

What are the main types of scarring alopecia?

Frontal fibrosing alopecia (FFA) causes progressive recession of the frontal and temporal hairline, often with a pale, featureless band of skin at the leading edge where follicle openings are absent. Eyebrow and body hair loss frequently accompanies scalp involvement. FFA occurs predominantly in postmenopausal women (mean age of onset 56–63 years), though it increasingly affects premenopausal women and men 2Ref 2Porriño-Bustamante ML, Fernández-Pugnaire MA, Arias-Santiago S (2021).Frontal Fibrosing Alopecia: A Review.FFA epidemiology (postmenopausal predominance, mean onset age, increasing worldwide incidence), diagnostic delay of 3.4–5.3 years, treatment outcomes (finasteride, dutasteride, intralesional corticosteroids, oral isotretinoin), graft survival under 60% at 5 years post-transplant. Its incidence appears to be rising worldwide since its first description in 1994, leading to suspicion of an environmental trigger — though the cause remains incompletely understood 2Ref 2Porriño-Bustamante ML, Fernández-Pugnaire MA, Arias-Santiago S (2021).Frontal Fibrosing Alopecia: A Review.FFA epidemiology (postmenopausal predominance, mean onset age, increasing worldwide incidence), diagnostic delay of 3.4–5.3 years, treatment outcomes (finasteride, dutasteride, intralesional corticosteroids, oral isotretinoin), graft survival under 60% at 5 years post-transplant.

Lichen planopilaris (LPP) is among the most common primary scarring alopecias overall. It presents with patches of hair loss accompanied by redness, scaling, and follicular plugging at the active edges, often with burning or itching. It can affect men and women across a wide age range and can occur anywhere on the scalp 3Ref 3Fechine COC, Valente NYS, Romiti R (2022).Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features.Scalp biopsy as standard for definitive diagnosis; trichoscopy for guiding biopsy site; classification; treatment approaches including hydroxychloroquine, topical/intralesional corticosteroids, immunosuppressants; no validated treatment guidelines; histopathological similarity between LPP and FFA. Hydroxychloroquine is one of the most widely used systemic treatments; a landmark study introducing the Lichen Planopilaris Activity Index (LPPAI) found that 83% of LPP patients showed significant improvement in disease activity scores after 12 months of hydroxychloroquine 4Ref 4Chiang C, Sah D, Cho BK, Ochoa BE, Price VH (2010).Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system.Hydroxychloroquine efficacy in LPP: 83% of patients showed significant improvement in LPPAI at 12 months; introduction of standardized disease activity scoring.

Central centrifugal cicatricial alopecia (CCCA) starts at the crown and spreads outward in a centrifugal pattern. It is significantly more common in women of African descent, with prevalence estimates of 2.7–5.7% in that population 5Ref 5Herskovitz I, Miteva M (2016).Central centrifugal cicatricial alopecia: challenges and solutions.CCCA prevalence in women of African descent (2.7–5.7%); hairstyling associations and multifactorial etiology; histological features; treatment approach. Its cause is multifactorial: certain hairstyling practices have been associated with CCCA for years, but studies do not confirm this as the sole factor. A landmark 2019 study in the New England Journal of Medicine identified variants in the *PADI3* gene — which encodes a protein essential to hair-shaft formation — in approximately 24% of CCCA patients, pointing to an inherited susceptibility 6Ref 6Malki L, Sarig O, Romano MT, et al. (2019).Variant PADI3 in Central Centrifugal Cicatricial Alopecia.PADI3 gene variants identified in approximately 24% of CCCA patients; role of PADI3 in hair-shaft formation; genetic susceptibility as component of CCCA etiology.

Discoid lupus erythematosus (DLE) causes reddish, scaly, scarring patches on the scalp and can also affect sun-exposed skin elsewhere. It is important to recognize because it may signal underlying systemic lupus; autoimmune evaluation is typically part of the workup when DLE is suspected.

These are not the only types — additional, rarer primary scarring alopecias exist. A dermatologist experienced in hair disorders can evaluate the full picture.

How is scarring alopecia diagnosed?

Scarring alopecias are frequently misdiagnosed early on — mistaken for dandruff, pattern hair loss, or contact dermatitis. Delayed diagnosis is common: in FFA, for example, the average lag between symptom onset and correct diagnosis has been reported as 3.4 to 5.3 years 2Ref 2Porriño-Bustamante ML, Fernández-Pugnaire MA, Arias-Santiago S (2021).Frontal Fibrosing Alopecia: A Review.FFA epidemiology (postmenopausal predominance, mean onset age, increasing worldwide incidence), diagnostic delay of 3.4–5.3 years, treatment outcomes (finasteride, dutasteride, intralesional corticosteroids, oral isotretinoin), graft survival under 60% at 5 years post-transplant. This delay can translate directly into unnecessary permanent follicle loss.

Scalp biopsy is the standard for definitive diagnosis 3Ref 3Fechine COC, Valente NYS, Romiti R (2022).Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features.Scalp biopsy as standard for definitive diagnosis; trichoscopy for guiding biopsy site; classification; treatment approaches including hydroxychloroquine, topical/intralesional corticosteroids, immunosuppressants; no validated treatment guidelines; histopathological similarity between LPP and FFA. A small punch biopsy taken from an active edge of the affected area shows the type and degree of inflammation, confirms fibrosis, and distinguishes the specific subtype of scarring alopecia — a distinction that matters because different types respond to different treatments.

Trichoscopy (dermoscopy of the scalp and hair) is a non-invasive tool that reveals characteristic features at the follicle level — absence of follicle openings, perifollicular scaling, and redness patterns — that strongly support a scarring diagnosis and help identify the best biopsy site 3Ref 3Fechine COC, Valente NYS, Romiti R (2022).Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features.Scalp biopsy as standard for definitive diagnosis; trichoscopy for guiding biopsy site; classification; treatment approaches including hydroxychloroquine, topical/intralesional corticosteroids, immunosuppressants; no validated treatment guidelines; histopathological similarity between LPP and FFA.

When DLE or systemic lupus is suspected, an autoimmune blood panel (including ANA and anti-dsDNA) is typically part of the evaluation. If hydroxychloroquine treatment is being considered, a baseline ophthalmology examination is standard because the medication can rarely affect the retina over time.

What does treatment aim to do — and what can it realistically achieve?

There is currently no treatment that reverses follicle scarring. The goal of all available therapies is to reduce inflammation, slow or stop the destruction of remaining follicles, and minimize symptoms like burning, pain, and itching 3Ref 3Fechine COC, Valente NYS, Romiti R (2022).Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features.Scalp biopsy as standard for definitive diagnosis; trichoscopy for guiding biopsy site; classification; treatment approaches including hydroxychloroquine, topical/intralesional corticosteroids, immunosuppressants; no validated treatment guidelines; histopathological similarity between LPP and FFA. This is disease control, not cure — and realistic expectations matter.

Treatment choice depends on the specific type of scarring alopecia, since these are distinct diseases with different underlying mechanisms. Options a dermatologist might use include:

• Topical and intralesional corticosteroids — often first-line, particularly for localized or early disease
• Oral immunomodulators — hydroxychloroquine is widely used for LPP and FFA; methotrexate and mycophenolate mofetil are used in refractory cases
• 5-alpha reductase inhibitors (finasteride, dutasteride) — considered among the most promising options for FFA; dutasteride has shown 44% improvement and 56% stabilization in some studies 2Ref 2Porriño-Bustamante ML, Fernández-Pugnaire MA, Arias-Santiago S (2021).Frontal Fibrosing Alopecia: A Review.FFA epidemiology (postmenopausal predominance, mean onset age, increasing worldwide incidence), diagnostic delay of 3.4–5.3 years, treatment outcomes (finasteride, dutasteride, intralesional corticosteroids, oral isotretinoin), graft survival under 60% at 5 years post-transplant
• Tetracycline-class antibiotics — used in CCCA and some other types for their anti-inflammatory properties
• Calcineurin inhibitors (topical tacrolimus, pimecrolimus) — adjunctive options
• Avoiding triggers — modifying hairstyling practices is part of CCCA management, though the approach should be handled sensitively given longstanding and sometimes inaccurate cultural narratives about causation

No treatment has been validated in rigorous randomized controlled trials for most types. Response is measured by slowing of progression, not by hair regrowth.

Can hair transplantation help after scarring alopecia?

Hair transplantation into previously scarred areas is occasionally pursued once disease is considered stable and quiescent. The critical requirement is confirmed inactivity: transplanting into an area with ongoing inflammation will result in the destruction of grafted follicles, just as the original follicles were destroyed.

Outcomes in scarring alopecia are more variable than in non-scarring types. A systematic review found that 26 of 34 patients experienced moderate to positive results, while 8 experienced negative results or disease recurrence 7Ref 7Ekelem C, Pham C, Atanaskova Mesinkovska N (2019).A Systematic Review of the Outcome of Hair Transplantation in Primary Scarring Alopecia.26 of 34 patients had moderate to positive hair transplant outcomes; 8 had negative results or disease recurrence; better outcomes in DLE and CCCA, more variable in LPP and FFA; publication bias concern noted. Results vary considerably by diagnosis — better outcomes have been reported in DLE and CCCA; results in LPP and FFA are more mixed 7Ref 7Ekelem C, Pham C, Atanaskova Mesinkovska N (2019).A Systematic Review of the Outcome of Hair Transplantation in Primary Scarring Alopecia.26 of 34 patients had moderate to positive hair transplant outcomes; 8 had negative results or disease recurrence; better outcomes in DLE and CCCA, more variable in LPP and FFA; publication bias concern noted. A separate review of FFA specifically noted graft survival of under 60% at five years 2Ref 2Porriño-Bustamante ML, Fernández-Pugnaire MA, Arias-Santiago S (2021).Frontal Fibrosing Alopecia: A Review.FFA epidemiology (postmenopausal predominance, mean onset age, increasing worldwide incidence), diagnostic delay of 3.4–5.3 years, treatment outcomes (finasteride, dutasteride, intralesional corticosteroids, oral isotretinoin), graft survival under 60% at 5 years post-transplant, which is meaningfully lower than transplantation in androgenetic alopecia.

Transplantation in this context is a secondary option pursued after sustained disease stability — not a first-line approach and not a substitute for treating active disease.

What to expect from follow-up and monitoring

Scarring alopecias are typically chronic conditions that wax and wane. Some people experience periods of active inflammation followed by relative quiescence; others have slow, steady progression. Monitoring is an ongoing part of management — typically through clinical examination, trichoscopy, and sometimes repeat biopsy.

Time-series photographs of the scalp, taken consistently over months, are one of the most practical tools for tracking progression at home and providing useful information at clinic visits. Standardized activity indices (such as the LPPAI 4Ref 4Chiang C, Sah D, Cho BK, Ochoa BE, Price VH (2010).Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system.Hydroxychloroquine efficacy in LPP: 83% of patients showed significant improvement in LPPAI at 12 months; introduction of standardized disease activity scoring) allow clinicians to compare disease activity over time more objectively.

The realistic long-term picture is this: with early diagnosis and consistent treatment, many people can achieve stabilization — meaning no further loss. That outcome is not guaranteed, and it depends substantially on how much disease activity was present before effective treatment began.